Correlation Between Enorama Pharma and Sprint Bioscience

Can any of the company-specific risk be diversified away by investing in both Enorama Pharma and Sprint Bioscience at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enorama Pharma and Sprint Bioscience into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enorama Pharma AB and Sprint Bioscience AB, you can compare the effects of market volatilities on Enorama Pharma and Sprint Bioscience and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enorama Pharma with a short position of Sprint Bioscience. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enorama Pharma and Sprint Bioscience.

Diversification Opportunities for Enorama Pharma and Sprint Bioscience

-0.78

Correlation Coefficient

Enorama Pharma  Sprint Bioscience

Pay attention - limited upside

The 3 months correlation between Enorama and Sprint is -0.78. Overlapping area represents the amount of risk that can be diversified away by holding Enorama Pharma AB and Sprint Bioscience AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sprint Bioscience and Enorama Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enorama Pharma AB are associated (or correlated) with Sprint Bioscience. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sprint Bioscience has no effect on the direction of Enorama Pharma i.e., Enorama Pharma and Sprint Bioscience go up and down completely randomly.

Pair Corralation between Enorama Pharma and Sprint Bioscience

Assuming the 90 days trading horizon Enorama Pharma AB is expected to under-perform the Sprint Bioscience. In addition to that, Enorama Pharma is 1.05 times more volatile than Sprint Bioscience AB. It trades about -0.04 of its total potential returns per unit of risk. Sprint Bioscience AB is currently generating about 0.11 per unit of volatility. If you would invest  131.00  in Sprint Bioscience AB on September 3, 2024 and sell it today you would earn a total of  40.00  from holding Sprint Bioscience AB or generate 30.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Enorama Pharma AB  vs.  Sprint Bioscience AB

Enorama Pharma AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Sprint Bioscience

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Sprint Bioscience AB are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Sprint Bioscience sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Enorama Pharma and Sprint Bioscience

The main advantage of trading using opposite Enorama Pharma and Sprint Bioscience positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enorama Pharma position performs unexpectedly, Sprint Bioscience can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sprint Bioscience will offset losses from the drop in Sprint Bioscience's long position.

The idea behind Enorama Pharma AB and Sprint Bioscience AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.